Cornerstone Robotics vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urologic clinical trial launched.
About
Cornerstone Robotics is a surgical robotics company whose Sentire Endoscopic Surgical System uses multiple robotic arms to enable minimally invasive surgery with enhanced dexterity beyond single-arm laparoscopic systems. The company raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. Sentire has received China National Medical Products Administration (NMPA) approval and launched UK clinical trials for colorectal and urologic procedures in 2025, with 2026 as its international commercialization ramp year.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.